Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

Phase 3

EQ001 (Itolizumab) (monoclonal antibody that targets CD6-ALCAM)

aGVHD (acute graft-versushost disease )

Q1 2025

EQUATE/EQUATOR study. 5/14/24 Interim enrollment achieved. 8/6/24- Positive Interim analysis , IDMC recommended continuation of trial. 11/13/24- Topline data in Q1 2025.

Data readout

MURA

Phase 3

Nemvaleukin alfa + pembrolizumab

Platinum-resistant ovarian cancer

Late Q1 or early Q2 2025

ARTISTRY-7. 3/11/25- Interim data readout in Late Q1/early Q2 2025.

Data readout

AXSM

Phase 3

Solriamfetol

Major depressive disorder

Q1 2025

PARADIGM trial. 3/19/24 Initiates Ph3 trial. 2/18/25- Topline data in Q1 2025.

Data readout

AXSM

Phase 3

Solriamfetol

Adults with ADHD

Q1 2025

FOCUS trial: 8/7/23- Trial initiated. 2/18/25- Topline data in Q1 2025.

Data readout

EYPT

Phase 2

DURAVYU (EYP-1901)

DME (Diabetic Macular Edema)

Q1 2025

VERONA trial. 1/10/24- First patient dosed. 6/26/24 Complete enrollment. 10/28/24- Reported interim 16 Wk data. 2/5/25- Reported six-month results, met primary endpoint. 3/5/25- Topline data in Q1 2025.

Data readout

RVPH

Phase 3

Brilaroxazine

Schizophrenia

Q1 2025

Suspected mover in December '24: RECOVER studies. 11/14/24- Topline 1-yr OLE data in December 2024. Full data analysis by Q1 2025. Initiate RECOVER-2 trial in Q1 2025 w/ topline data in Q4 2025. NDA submission in Q2 2026. 12/16/24- Favorable long-term safety & efficacy data. Full data set in Q1 2025.

Additional Data readout

MDNAF

Phase 1/2

MDNA11 (IL-2)

Cold tumors

Q1 & Q2 2025

ABILITY-1 trial. Collab w/ MERCK. 2/13/24- First patient dosed. 11/11/24- Monotherapy DE data presentation at SITC '24. 12/5/24- Clinical update. Present add'l monotherapy & combo clinical data at medical conferences in Q1 and Q2 of 2025.

Data readout

AUTL

Phase 1

obe-cel (AUTO1) (CD19)

SLE

Q1 2025

CARLYSLE study. 11/15/23- Ph1 study to start in early 2024. 1/13/25- Report initial data in Q1 2025 and at an R&D investor event on April 23, 2025. Present data at a medical conference in H2 2025.

Data readout

VSTM

Phase 1/2

Avutometinib (VS-6766), + defactinib+gemcitabine/nab-paclitaxel

Metastatic pancreatic cancer

Q1 2025

RAMP 205 study. Initiated Ph1b/2 clinical trial & enrollment ongoing. Presented initial data at ASCO '24. 7/29/24- Orphan Drug Designation. Report updated data in Q1 2025.

Data Readout

DRMA

Phase 3

DMT310

Acne

End of March 2025

STAR-1 and STAR-2 trials. 12/20/23- FPI in STAR-1. 3/4/25- Last patient completed last visit. 3/17/25- Topline data by end of March 2025. Initiate START-2 trial if STAR-1 yields positive results.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20